Labeler
Pfizer Laboratories Div Pfizer Inc NDC Codes
Pfizer Laboratories Div Pfizer Inc lists 236 finished drug products in the FDA NDC Directory under NDC labeler codes 0013, 0025, 0069, 60793, 72618.
Overview
Each product below links to its own NDC page with package NDCs in 10- and 11-digit form.
- Drugs
- Doxorubicin Hydrochloride, Octagam Immune Globulin (Human), Caduet, Talzenna, Cutaquig, Paxlovid, Comirnaty, Hympavzi, Abrilada, Xalkori, Cibinqo, Propofol, Ibrance, Thrombin-Jmi, Bosulif
- Active ingredients
- Human immunoglobulin g, Doxorubicin hydrochloride, Amlodipine besylate, Atorvastatin calcium trihydrate, Talazoparib tosylate, Marstacimab, Crizotinib, Abrocitinib, Propofol, Palbociclib, Thrombin, Bnt-162b2 omicron (Xfg) mrna
- NDC labeler codes
- 0013, 0025, 0069, 60793, 72618
- Strengths (from the 100 most recently listed products)
- Doxorubicin hydrochloride 2 mg/mL; Human immunoglobulin g 100 mg/mL; Human immunoglobulin g 165 mg/mL; Human immunoglobulin g 50 mg/mL; Amlodipine besylate 5 mg/1; Amlodipine besylate 10 mg/1; Propofol 10 mg/mL; Marstacimab 150 mg/mL; Talazoparib tosylate .5 mg/1; Atorvastatin calcium trihydrate 80 mg/1; Atorvastatin calcium trihydrate 20 mg/1; Atorvastatin calcium trihydrate 40 mg/1; Atorvastatin calcium trihydrate 10 mg/1; Rimegepant sulfate 75 mg/1; Thrombin 5000 [iU]/5mL; Bnt-162b2 omicron (Xfg) mrna .0158 mg/.48mL; Bnt-162b2 omicron (Xfg) mrna .042 mg/.418mL; Marstacimab 75 mg/.5mL; Thrombin 20000 [iU]/20mL; Leucovorin calcium 5 mg/1
- Dosage forms
- Injection, Solution, Solution, Tablet, Film coated, Kit, Capsule, Liquid filled, Injection, Suspension, Capsule, Capsule, Coated pellets, Injection, Injection, Emulsion, Liquid, Injection, Powder, Lyophilized, For solution, Tablet, Orally disintegrating, Tablet, System, Spray, Tablet, Film coated, Extended release
- Routes
- Oral, Intravenous, Subcutaneous, Intramuscular, Topical, Vaginal, Nasal
- Drug classes (FDA established)
- Human Immunoglobulin G, Anthracycline Topoisomerase Inhibitor, Kinase Inhibitor, Calcium Channel Blocker, Dihydropyridine Calcium Channel Blocker, HMG-CoA Reductase Inhibitor, Poly(ADP-Ribose) Polymerase Inhibitor, Janus Kinase Inhibitor, Calcitonin Gene-related Peptide Receptor Antagonist, General Anesthetic, Blood Coagulation Factor, Recombinant Human Growth Hormone, Erythropoiesis-stimulating Agent, CD20-directed Cytolytic Antibody, Vascular Endothelial Growth Factor Inhibitor, Folate Analog, Sphingosine 1-phosphate Receptor Modulator, Estrogen, Anti-coagulant, Low Molecular Weight Heparin, HER2/neu Receptor Antagonist, Leukocyte Growth Factor
- HCPCS / J-code
- CPT 90678 — Vaccine product code for ABRYSVO (respiratory syncytial virus vaccine, bivalent), J9355 — Injection, trastuzumab, excludes biosimilar, 10 mg, J2506 — Injection, pegfilgrastim, excludes biosimilar, 0.5 mg, J9312 — Injection, rituximab, 10 mg, J9035 — Injection, bevacizumab, 10 mg
- Package NDCs
- 108 (from the 100 most recently listed products)
NDC codes
Newest listings first. Each row links to the product’s NDC page.
| Product | Strength | Form · route | Product NDC | Package NDCs (11-digit) | HCPCS |
|---|---|---|---|---|---|
| Paxlovidnirmatrelvir and ritonavir | — | Kit | 0069-5321 | 00069-5321-30 | — |
| Elrexfioelranatamab-bcmm | Elranatamab 44 mg/1.1mL | Injection, SolutionSubcutaneous | 0069-2522 | 00069-2522-02 | — |
| Elrexfioelranatamab-bcmm | Elranatamab 76 mg/1.9mL | Injection, SolutionSubcutaneous | 0069-4494 | 00069-4494-02 | — |
| Ngenlasomatrogon-ghla | Somatrogon 60 mg/1.2mL | Injection, SolutionSubcutaneous | 0069-0520 | 00069-0520-02 | — |
| Ngenlasomatrogon-ghla | Somatrogon 24 mg/1.2mL | Injection, SolutionSubcutaneous | 0069-0505 | 00069-0505-02 | — |
| Litfuloritlecitinib | Ritlecitinib tosylate 50 mg/1 | CapsuleOral | 0069-0334 | 00069-0334-28 | — |
| Estringestradiol | Estradiol 2 mg/1 | SystemVaginal | 0013-1042 | 00013-1042-01 | — |
| Zavzpretzavegepant | Zavegepant hydrochloride 10 mg/.1mL | SprayNasal | 0069-3500 | 00069-3500-02 | — |
| Fragmindalteparin sodium | Dalteparin sodium 2500 [iU]/mL | InjectionSubcutaneous | 0069-0253 | 00069-0253-10 | — |
| Caduetamlodipine and atorvastatin | Amlodipine besylate 5 mg/1; Atorvastatin calcium trihydrate 80 mg/1 | Tablet, Film coatedOral | 0069-6747 | 00069-6747-30 | — |
| Caduetamlodipine and atorvastatin | Amlodipine besylate 10 mg/1; Atorvastatin calcium trihydrate 80 mg/1 | Tablet, Film coatedOral | 0069-7476 | 00069-7476-30 | — |
| Caduetamlodipine and atorvastatin | Amlodipine besylate 5 mg/1; Atorvastatin calcium trihydrate 20 mg/1 | Tablet, Film coatedOral | 0069-6323 | 00069-6323-30 | — |
| Caduetamlodipine and atorvastatin | Amlodipine besylate 10 mg/1; Atorvastatin calcium trihydrate 40 mg/1 | Tablet, Film coatedOral | 0069-7654 | 00069-7654-30 | — |
| Caduetamlodipine and atorvastatin | Amlodipine besylate 5 mg/1; Atorvastatin calcium trihydrate 10 mg/1 | Tablet, Film coatedOral | 0069-6180 | 00069-6180-30 | — |
| Caduetamlodipine and atorvastatin | Amlodipine besylate 10 mg/1; Atorvastatin calcium trihydrate 20 mg/1 | Tablet, Film coatedOral | 0069-7232 | 00069-7232-30 | — |
| Caduetamlodipine and atorvastatin | Amlodipine besylate 5 mg/1; Atorvastatin calcium trihydrate 40 mg/1 | Tablet, Film coatedOral | 0069-6565 | 00069-6565-30 | — |
| TicoVactick-borne encephalitis vaccine | Tick-borne encephalitis purified antigen (Formaldehyde inactivated) 1.2 ug/.25mL | InjectionIntramuscular | 0069-0297 | 00069-0297-0200069-0297-10 | — |
| Caduetamlodipine and atorvastatin | Amlodipine besylate 10 mg/1; Atorvastatin calcium trihydrate 10 mg/1 | Tablet, Film coatedOral | 0069-7810 | 00069-7810-30 | — |
| Cibinqoabrocitinib | Abrocitinib 100 mg/1 | Tablet, Film coatedOral | 0069-0335 | 00069-0335-30 | — |
| Cibinqoabrocitinib | Abrocitinib 200 mg/1 | Tablet, Film coatedOral | 0069-0435 | 00069-0435-30 | — |
| Cibinqoabrocitinib | Abrocitinib 50 mg/1 | Tablet, Film coatedOral | 0069-0235 | 00069-0235-30 | — |
| Talzennatalazoparib | Talazoparib tosylate .5 mg/1 | CapsuleOral | 0069-1501 | 00069-1501-30 | — |
| TicoVactick-borne encephalitis vaccine | Tick-borne encephalitis purified antigen (Formaldehyde inactivated) 2.4 ug/.5mL | InjectionIntramuscular | 0069-0411 | 00069-0411-0200069-0411-10 | — |
| Trazimeratrastuzumab-qyyp | Trastuzumab 150 mg/7.15mL | Injection, Powder, Lyophilized, For solutionIntravenous | 0069-0308 | 00069-0308-01 | J9355 |
| Xeljanztofacitinib | Tofacitinib citrate 1 mg/mL | SolutionOral | 0069-1029 | 00069-1029-02 | — |
| Nyvepriapegfilgrastim-apgf | Pegfilgrastim 6 mg/.6mL | Injection, SolutionSubcutaneous | 0069-0324 | 00069-0324-01 | J2506 |
| Retacritepoetin alfa-epbx | Epoetin 20000 [iU]/mL | Injection, SolutionIntravenous, Subcutaneous | 0069-1311 | 00069-1311-10 | — |
| Retacritepoetin alfa-epbx | Epoetin 10000 [iU]/mL | Injection, SolutionIntravenous, Subcutaneous | 0069-1318 | 00069-1318-10 | — |
| Propofol | Propofol 10 mg/mL | Injection, EmulsionIntravenous | 0069-0234 | 00069-0234-20 | — |
| Propofol | Propofol 10 mg/mL | Injection, EmulsionIntravenous | 0069-0248 | 00069-0248-10 | — |
| Propofol | Propofol 10 mg/mL | Injection, EmulsionIntravenous | 0069-0209 | 00069-0209-10 | — |
| Ibrancepalbociclib | Palbociclib 125 mg/1 | Tablet, Film coatedOral | 0069-0688 | 00069-0688-03 | — |
| Ibrancepalbociclib | Palbociclib 100 mg/1 | Tablet, Film coatedOral | 0069-0486 | 00069-0486-03 | — |
| Ibrancepalbociclib | Palbociclib 75 mg/1 | Tablet, Film coatedOral | 0069-0284 | 00069-0284-03 | — |
| Nurtec ODTrimegepant sulfate | Rimegepant sulfate 75 mg/1 | Tablet, Orally disintegratingOral | 72618-3000 | 72618-3000-02 | — |
| Nurtec ODTrimegepant sulfate | Rimegepant sulfate 75 mg/1 | Tablet, Orally disintegratingOral | 72618-3001 | 72618-3001-0272618-3001-04 | — |
| Trazimeratrastuzumab-qyyp | — | Kit | 0069-0305 | 00069-0305-01 | — |
| Ruxiencerituximab-pvvr | Rituximab 100 mg/10mL | Injection, SolutionIntravenous | 0069-0238 | 00069-0238-01 | J9312 |
| Ruxiencerituximab-pvvr | Rituximab 500 mg/50mL | Injection, SolutionIntravenous | 0069-0249 | 00069-0249-01 | J9312 |
| Xeljanz XRtofacitinib | Tofacitinib citrate 22 mg/1 | Tablet, Film coated, Extended releaseOral | 0069-0502 | 00069-0502-30 | — |
| Zirabevbevacizumab-bvzr | Bevacizumab 100 mg/4mL | Injection, SolutionIntravenous | 0069-0315 | 00069-0315-01 | J9035 |
| Zirabevbevacizumab-bvzr | Bevacizumab 400 mg/16mL | Injection, SolutionIntravenous | 0069-0342 | 00069-0342-01 | J9035 |
| Cutaquigimmunoglobulin g | Human immunoglobulin g 165 mg/mL | SolutionSubcutaneous | 0069-1802 | 00069-1802-02 | — |
| Cutaquigimmunoglobulin g | Human immunoglobulin g 165 mg/mL | SolutionSubcutaneous | 0069-1476 | 00069-1476-02 | — |
| Cutaquigimmunoglobulin g | Human immunoglobulin g 165 mg/mL | SolutionSubcutaneous | 0069-1960 | 00069-1960-02 | — |
| Cutaquigimmunoglobulin g | Human immunoglobulin g 165 mg/mL | SolutionSubcutaneous | 0069-1509 | 00069-1509-02 | — |
| Cutaquigimmunoglobulin g | Human immunoglobulin g 165 mg/mL | SolutionSubcutaneous | 0069-1061 | 00069-1061-02 | — |
| Cutaquigimmunoglobulin g | Human immunoglobulin g 165 mg/mL | SolutionSubcutaneous | 0069-1965 | 00069-1965-02 | — |
| Vyndamaxtafamidis | Tafamidis 61 mg/1 | Capsule, Liquid filledOral | 0069-8730 | 00069-8730-30 | — |
| Panzygaimmune globulin intravenous (human) | Human immunoglobulin g 100 mg/mL | SolutionIntravenous | 0069-1415 | 00069-1415-02 | — |
Pfizer Laboratories Div Pfizer Inc: common questions
- What is Pfizer Laboratories Div Pfizer Inc's NDC labeler code?
- 0013, 0025, 0069, 60793, 72618. The labeler code is the first segment of each NDC. About labeler codes.
- Is there a J-code for Pfizer Laboratories Div Pfizer Inc?
- Med-Code's HCPCS directory matches CPT 90678, J9355, J2506, J9312, J9035 to these products. NDC vs J-code.
- Which NDC goes on a claim?
- The package NDC of what was given, in 11-digit form. How to convert a 10-digit NDC.